Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorYi Tian
About this trial
A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.
Eligibility criteria
Qualifiers
Patients with a high suspicion of oncological diseases.
Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.
Disqualifiers
Failure to sign the informed consent form.
Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.
Severe cardiac dysfunction, cardiac function class III-IV.
Renal failure (serum creatinine level > 1.2 mg/dl).
Trial design
Treatments tested in this trial
- 68Ga-FXX489
- Positron Emission Tomography (PET) imaging
- Gallium-68 labelled (68Ga-) FAP-2286
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Yi Tian
Lead sponsor
First Hospital of China Medical University
Sponsor institution
Source ClinicalTrials.gov